M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Radiologic Pathologic Correlation of Imaging to Distinguish True Progression from Pseudoprogression in Brain Malignancies

Phase 1

Recruiting

Conditions: Pseudoprogression
Brain Malignancies

Interventions: Procedure: MRI Scan
Procedure: CT Scan
Procedure: Biopsy

First Posted Date: 2024-01-10

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT06199479

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Nab-paclitaxel
Drug: YL-13027

First Posted Date: 2024-01-10

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT06199466

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Intelligent Optical Probe for Guiding Core Needle Biopsy Procedures

Not Applicable

Recruiting

Conditions: Needle Biopsy

Interventions: Device: tVisio-1

First Posted Date: 2024-01-10

Last Posted Date: 2024-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT06199492

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

Phase 3

Recruiting

Conditions: Misuse, Opioid

Interventions: Drug: Olanzapine
Drug: Placebo

First Posted Date: 2024-01-10

Last Posted Date: 2024-12-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 87

Registration Number: NCT06200181

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: ASTX727
Drug: Venetoclax

First Posted Date: 2024-01-05

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06191978

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

Early Phase 1

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Biological: Alteplase
Drug: Placebo Administration

First Posted Date: 2023-12-28

Last Posted Date: 2024-12-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06184321

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Recruiting

Conditions: Lymphopenia
Pneumococcal Vaccine
Esophageal Cancer
Chemoradiation

Interventions: Biological: Pneumonia vaccine

First Posted Date: 2023-12-26

Last Posted Date: 2024-05-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT06181656

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)

Phase 2

Recruiting

Conditions: Oropharyngeal Neoplasms
Robotic Surgery and/or Radiotherapy
Lymphoscintigraphy

Interventions: Radiation: Arm 1- Ipsilateral

First Posted Date: 2023-12-12

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 240

Registration Number: NCT06167291

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Phase 4

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Methylnaltrexone

First Posted Date: 2023-12-08

Last Posted Date: 2024-07-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT06162377

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

Not Applicable

Recruiting

Conditions: Chemotherapy-induced Peripheral Neuropathy
Peripheral Nerve Stimulation

Interventions: Other: Peripheral Nerve Stimulation

First Posted Date: 2023-12-08

Last Posted Date: 2024-06-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT06162403

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy